Summary
The publisher, the industry analysis specialist, has released its latest report, “Denmark - Healthcare, Regulatory and Reimbursement Landscape”. The report is an essential source of information on analysis of the healthcare, regulatory and reimbursement landscape in Denmark. It identifies the key trends in the country’s healthcare market and provides insights into its demographic, regulatory and reimbursement landscape, and healthcare infrastructure. Most importantly, the report provides valuable insights into the trends and segmentation of its pharmaceutical and medical device markets. It uses data and information sourced from proprietary databases, secondary research, and in-house analysis by the publisher’s team of industry experts.
The Danish pharmaceutical market, in terms of Danish Krone, increased from DKK20.5B in 2011 to DKK24.7B in 2019 at a Compound Annual Growth Rate (CAGR) of 1.7%. However, in terms of US Dollars, the market decreased slightly from $3.8B in 2011 to $3.7B in 2019 at a negative CAGR of 0.4%. This difference was due to the currency fluctuation between the US Dollar and the Danish Krone. The medical devices market of Denmark was $1.7B in 2015, which increased at a CAGR of 3.3% to reach $1.94B in 2019. The market is expected to grow at a CAGR of 4.4% from $2.01B in 2020 to reach $2.51B in 2025. In March 2018, the government of Denmark introduced a five-year plan to boost the pharmaceutical industry. The plan’s initiatives are spread across six focus areas, such as improving the framework conditions for research and development activities and conducting clinical trials, boosting the Danish Medicines Agency (DKMA), and enhancing access to qualified and skilled labor.
Scope
The report provides information on the healthcare, regulatory, and reimbursement landscape in Denmark, and includes -
Reasons to Buy
This report will enhance your decision-making capability by allowing you to -
The publisher, the industry analysis specialist, has released its latest report, “Denmark - Healthcare, Regulatory and Reimbursement Landscape”. The report is an essential source of information on analysis of the healthcare, regulatory and reimbursement landscape in Denmark. It identifies the key trends in the country’s healthcare market and provides insights into its demographic, regulatory and reimbursement landscape, and healthcare infrastructure. Most importantly, the report provides valuable insights into the trends and segmentation of its pharmaceutical and medical device markets. It uses data and information sourced from proprietary databases, secondary research, and in-house analysis by the publisher’s team of industry experts.
The Danish pharmaceutical market, in terms of Danish Krone, increased from DKK20.5B in 2011 to DKK24.7B in 2019 at a Compound Annual Growth Rate (CAGR) of 1.7%. However, in terms of US Dollars, the market decreased slightly from $3.8B in 2011 to $3.7B in 2019 at a negative CAGR of 0.4%. This difference was due to the currency fluctuation between the US Dollar and the Danish Krone. The medical devices market of Denmark was $1.7B in 2015, which increased at a CAGR of 3.3% to reach $1.94B in 2019. The market is expected to grow at a CAGR of 4.4% from $2.01B in 2020 to reach $2.51B in 2025. In March 2018, the government of Denmark introduced a five-year plan to boost the pharmaceutical industry. The plan’s initiatives are spread across six focus areas, such as improving the framework conditions for research and development activities and conducting clinical trials, boosting the Danish Medicines Agency (DKMA), and enhancing access to qualified and skilled labor.
Scope
The report provides information on the healthcare, regulatory, and reimbursement landscape in Denmark, and includes -
- An overview of the pharmaceutical and medical device markets, comprising market size, segmentation, and key drivers and barriers
- Profiles and SWOT analyses of the major players in the pharmaceutical market: GlaxoSmithKline, Pfizer, Lundbeck, Novo Nordisk, and Leo Pharma
- Profiles and SWOT analyses of the major players in the medical device market: Abbott, Alcon, GE Healthcare, Fresenius, and Roche Diagnostics
- An insightful review of the COVID-19 epidemiology, COVID-19 impact and developments in healthcare market, HealthTech landscape, reimbursement and regulatory landscape, with analysis covering details of the country’s healthcare reimbursement process, regulatory agencies and the approval processes for new drugs and medical devices
- Detailed analysis of the country’s healthcare policy highlights, demographics, healthcare infrastructure and healthcare expenditure
- An overview of the opportunities for and challenges to growth in the Danish healthcare market
Reasons to Buy
This report will enhance your decision-making capability by allowing you to -
- Develop business strategies by understanding the trends shaping and driving Denmark’s healthcare market
- Drive revenues by understanding the key trends, reimbursement and regulatory policies, pharmaceutical market segments and companies likely to impact Denmark’s healthcare market in the future
- Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing competitors’ performance
- Organize your sales and marketing efforts by identifying the market categories and segments that present the most opportunities for consolidation, investment and strategic partnership
Table of Contents
1. Table of Contents
2. Executive Summary
3. Overview of Pharmaceutical Market
4. Overview of Medical Devices Market
5. Pharmaceutical and Medical Devices Market - Drivers and Barriers
6. Deal Analysis
7. HealthTech Landscape
8. Market Access
9. Country Healthcare Landscape
List of Tables
List of Figures